Study of Eltrombopag in Platelet Refractory Thrombocytopenia

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2010

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
This phase II trial is studying the effects of the drug eltrombopag has on thrombocytopenia (low platelet count). Eltrombopag is approved by the FDA for the treatment of thrombocytopenia (low platelet count) in adults who have had an insufficient response to medications such as corticosteroids and immunoglobulins. Eltrombopag is not approved by the FDA (Food and Drug Administration) for the treatment of thrombocytopenia refractory to platelet transfusion and so for this study is considered investigational.
Epistemonikos ID: 91bd9e3172f3d76c24e057031f3788347e0e3493
First added on: May 05, 2024